Myasthenia gravis is an autoimmune neuromuscular disease where antibodies block acetylcholine receptors at the nerve-muscle junction, causing fluctuating muscle weakness that worsens with activity. It can range from mild eye involvement to respiratory crisis requiring ventilator support.
What's actually going on in research
FcRn inhibitors that accelerate the clearance of pathogenic antibodies from the blood — including efgartigimod and rozanolixizumab — are producing rapid improvement in generalized MG. Complement inhibitors like eculizumab and ravulizumab are now standard for severe generalized MG. Trials are testing these new mechanisms in thymoma-associated and seronegative MG, and early intervention to prevent crisis is being studied.
FcRn inhibitors
Drugs like efgartigimod reduce circulating AChR and MuSK antibody levels rapidly by blocking the receptor that recycles antibodies in the body, producing fast improvement in MG weakness.
Complement inhibitors
Eculizumab and ravulizumab block complement activation at the neuromuscular junction, reducing destruction of acetylcholine receptors. Trials are extending their use to earlier and milder disease.
B-cell depletion
Rituximab depletes antibody-producing B-cells in MG and is being tested in newly diagnosed generalized MG to achieve early remission and reduce long-term corticosteroid dependence.
What to know before you search
Eligibility depends on MG subtype (AChR-antibody positive vs. MuSK vs. seronegative), disease generalization, MGFA severity class, and prior immunosuppression.
What types of trials are currently open
- FcRn inhibitor trials — Testing efgartigimod, rozanolixizumab, and nipocalimab for rapid antibody clearance in generalized MG.
- Complement inhibitor trials — Evaluating eculizumab, ravulizumab, and newer complement drugs across MG subtypes.
- B-cell depletion trials — Testing rituximab as early-line therapy to achieve sustained remission in generalized MG.
- Thymectomy trials — Evaluating surgical thymectomy outcomes in non-thymomatous generalized MG.
- Seronegative MG trials — Testing treatments specifically for MuSK-positive and double-seronegative myasthenia gravis.
Recently added Myasthenia Gravis trials
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
This study is an open-label, exploratory, prospective clinical trial with dose escalation(according to "3+3" design), to evaluate the safety and tolerability of QH103(Universal CD19 CAR-γδT Cell Injection)in the treatment of recurrent/refractory antibody-mediated neurological autoimmune diseases.
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
Find Myasthenia Gravis trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.